Generation of autonomously pathogenic neo-autoreactive Th1 cells during the development of the determinant spreading cascade in murine autoimmune encephalomyelitis

J Neurosci Res. 1996 Aug 15;45(4):463-70. doi: 10.1002/(SICI)1097-4547(19960815)45:4<463::AID-JNR16>3.0.CO;2-1.

Abstract

Chronic progression of autoimmune disease is accompanied by the acquisition of autoreactivity to new self-determinants. Recent evidence indicates that this process, commonly referred to as determinant spreading, may be pathogenic for chronicity. Our studies on experimental autoimmune encephalomyelitis (EAE), a murine model widely used in multiple sclerosis (MS) studies, have shown that determinant spreading develops as a predictable sequential cascade of neo-autoimmunity during progression to chronic disease. By 7-8 weeks after immunization of (SWR x SJL)F1 mice with the immunodominant myelin proteolipid protein determinant (PLP 139-151), splenocytes consistently respond to the immunodominant myelin basic protein determinant (MBP 87-99). In the present study, we directly address the pathogenicity of neo-autoimmunity resulting from endogenous self-priming during the course of disease. Our results indicate that T cells responding to the spreading MBP 87-99 determinant produce a proinflammatory cytokine profile consistent with type 1 helper T cells (Th1) cells. In addition, splenocytes activated to the spreading MBP 87-99 determinant consistently transfer acute EAE in naive recipients even when T cells reactive to the priming PLP 139-151 immunogen are eliminated by bromodeoxyuridine (BUdR)-mediated photolysis. Our data indicate that endogenous neo-autoantigen priming during chronic autoimmune disease generates type 1 helper T cells (Th1) cells that are autonomously pathogenic. These results provide further evidence supporting the view that determinant spreading is a pathogenic process that leads to chronic progression of autoimmune disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adoptive Transfer
  • Animals
  • Antigen Presentation / immunology
  • Antimetabolites / pharmacology
  • Autoantigens / immunology
  • Autoantigens / pharmacology
  • Bisbenzimidazole / pharmacology
  • Bromodeoxyuridine / pharmacology
  • Central Nervous System Diseases / immunology
  • Central Nervous System Diseases / pathology
  • Cytokines / immunology
  • Cytokines / metabolism
  • Demyelinating Diseases / immunology
  • Encephalomyelitis, Autoimmune, Experimental / immunology*
  • Encephalomyelitis, Autoimmune, Experimental / prevention & control
  • Epitopes / immunology
  • Epitopes / pharmacology
  • Female
  • Fluorescent Dyes / pharmacology
  • Immunization
  • Mice
  • Mice, Inbred Strains
  • Myelin Basic Protein / immunology
  • Myelin Basic Protein / pharmacology
  • Myelin Proteins / immunology
  • Myelin Proteins / pharmacology
  • Myelin Proteolipid Protein*
  • Peptide Fragments / immunology
  • Peptide Fragments / pharmacology
  • Photochemistry
  • Spleen / cytology
  • Spleen / immunology
  • T-Lymphocytes, Helper-Inducer / drug effects
  • T-Lymphocytes, Helper-Inducer / immunology*
  • T-Lymphocytes, Helper-Inducer / pathology

Substances

  • Antimetabolites
  • Autoantigens
  • Cytokines
  • Epitopes
  • Fluorescent Dyes
  • Myelin Basic Protein
  • Myelin Proteins
  • Myelin Proteolipid Protein
  • Peptide Fragments
  • myelin proteolipid protein (139-151)
  • Bromodeoxyuridine
  • Bisbenzimidazole